Calidi Biotherapeutics, Inc. (CLDI) stock
CLDINYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as CLDWW
$0.56−0.04 (-7.07%)
Close on Nov 17, 2026Market cap $1.45MP/E –Yield –
Calidi Biotherapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Calidi Biotherapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $9.86M, up 9.8% year over year. For fiscal 2025 it was $9.74M, up 9.7% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.74M | +9.7% |
| FY2024 | Dec 31, 2024 | $8.88M | -31.7% |
| FY2023 | Dec 31, 2023 | $13.01M | +79.2% |
| FY2022 | Dec 31, 2022 | $7.26M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.56M | -1.3% |
| Q1 FY2026 | Mar 31, 2026 | $2.59M | +6.7% |
| Q4 FY2025 | Dec 31, 2025 | $2.36M | +29.9% |
| Q3 FY2025 | Sep 30, 2025 | $2.36M | +9.7% |
| Q2 FY2025 | Jun 30, 2025 | $2.59M | +19.7% |
| Q1 FY2025 | Mar 31, 2025 | $2.43M | -11.6% |
| Q4 FY2024 | Dec 31, 2024 | $1.82M | -54.1% |
| Q3 FY2024 | Sep 30, 2024 | $2.15M | -33.8% |
| Q2 FY2024 | Jun 30, 2024 | $2.17M | -31.8% |
| Q1 FY2024 | Mar 31, 2024 | $2.74M | +4.6% |
| Q4 FY2023 | Dec 31, 2023 | $3.96M | +74.9% |
| Q3 FY2023 | Sep 30, 2023 | $3.25M | +67.1% |
| Q2 FY2023 | Jun 30, 2023 | $3.18M | – |
| Q1 FY2023 | Mar 31, 2023 | $2.62M | – |
| Q4 FY2022 | Dec 31, 2022 | $2.26M | – |
| Q3 FY2022 | Sep 30, 2022 | $1.95M | – |
See a number that looks wrong?